3Q EARNINGS: Will Actavis, CEO Saunders continue deal streak?
This article was originally published in Scrip
Actavis won't let its massive debt position – $15.1bn as of the third quarter of 2014 – get in the way of its dealmaking track record, including large transactions, which may or may not include the specialty biopharmaceutical company Allergan.
You may also be interested in...
Allergan will pay $200m to exercise its option to buy Motus Therapeutics (formerly Rhythm Health) after what the pharma described as a successful Phase IIb study for relamorelin in diabetic gastroparesis.
Private Company Edition: Scrip spoke with DDF US partner Jonathan Behr about the convergence of emerging science, venture capital investment and rising big pharma interest in neurodegeneration. Also, in recent VC financings HotSpot raised $100m, while Curie and Ablaze debuted with $75m each.
The response rate, with five complete responses, exceeds known responses to standard-of-care chemotherapy in heavily pre-treated folate receptor alpha-high patients. A US FDA filing is on track for early 2022.